Medical products maker Baxter cuts 2025 forecast; shares plunge to 19-year low

Baxter International (BAX) shares plunged 23% after the company significantly cut its 2025 adjusted profit forecast to $2.42-$2.52 per share and reported disappointing Q2 earnings of $0.59 per share, missing estimates. The reduced outlook is driven by persistent softness in IV fluid demand due to lingering effects from Hurricane Helene and continued hospital conservation, with volumes expected to remain 20% below normal through 2025, compounded by a voluntary halt of Novum IQ Large Volume Pump shipments and underperformance in its pharmaceuticals unit. This signals ongoing operational challenges and a more cautious management stance, significantly impacting investor confidence.

Analysis

Baxter International (BAX) is facing a significant operational and financial crisis, evidenced by a 23% collapse in its share price to a low not seen since 2006. This was triggered by a material reduction in its 2025 adjusted earnings forecast to $2.42-$2.52 per share and a second-quarter earnings miss, with adjusted EPS of 59 cents falling short of the 61-cent estimate. The core of the problem lies in its medical products business, where persistent softness in IV fluid demand, a direct consequence of last year's Hurricane Helene, is expected to keep volumes 20% below normal for the remainder of 2025. This issue is compounded by a voluntary halt of Novum IQ Large Volume Pump shipments following reports of patient deaths and injuries, with no resumption expected before year-end. The weakness is not isolated, as the pharmaceuticals unit also underperformed with declining sales in both injectable drugs and anesthesia. Management's commentary signals a defensive posture, aiming to "capture more of the potential downside risks," which, as noted by JPMorgan, confirms investor fears that were brewing since a new CEO took over in July.

Key Decisions for Investors

• Given the severity of the guidance cut and multi-faceted operational headwinds, investors should brace for continued stock price volatility and heightened risk, as the 23% decline may not represent a floor.
• The projection of IV fluid volumes remaining 20% below normal through 2025 is a critical forward-looking metric to monitor, as any further deterioration would likely trigger additional downward earnings revisions.
• Closely track communications regarding the Novum IQ pump halt, as the timeline for resolution and the management of potential liabilities represent a significant near-term catalyst or a source of further downside risk.
• The new management's credibility is now under scrutiny; therefore, their forthcoming strategic plans to address these deep-seated issues in both medical products and pharmaceuticals are paramount for rebuilding investor confidence.